Status:
UNKNOWN
Development of a Prediction Platform for Neoadjuvant Treatment and Prognosis in Pancreatic Cancer Using Organoid
Lead Sponsor:
Samsung Medical Center
Conditions:
Pancreas Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from th...
Eligibility Criteria
Inclusion
- 18 years old or older
- Newly discovered pancreatic cancer and not a relapse
- Diagnosed with pancreatic cancer via EUS-FNA, EUS-FNB before surgery
- who is in need of neoadjuvant chemotherapy before surgery
- Patients who can undergo surgery for pancreatic cancer after neoadjuvant chemotherapy
- Diagnosed with pancreatic cancer from the final tissue pathology diagnosis after surgery
- Able to make decisions for oneself for participation
- Has obtained voluntary consent in written form (if 70 years of age or older, receive consent from the guardian as well)
Exclusion
- • None
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 7 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04777604
Start Date
March 1 2021
End Date
January 7 2026
Last Update
March 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 06351